CTX131
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Trial Timeline
Mar 13, 2023 → Sep 18, 2025
NCT ID
NCT05795595About CTX131
CTX131 is a phase 1/2 stage product being developed by CRISPR Therapeutics for Clear Cell Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05795595. Target conditions include Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma.
What happened to similar drugs?
3 of 13 similar drugs in Clear Cell Renal Cell Carcinoma were approved
Approved (3) Terminated (1) Active (9)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
9
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06492304 | Phase 1/2 | Recruiting |
| NCT05795595 | Phase 1/2 | Completed |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma